We continue our series of posts inspired by Drug Hunter’s “Molecules of the Month” (drughunter.com)!

A recently highlighted molecule by Drug Hunter (drughunter.com) is migoprotafib (GDC-1971) — an oral allosteric inhibitor of SHP2 now in Phase I for the treatment of solid tumors. Delving into the chemical space of analogs for this drug candidate may unlock new perspectives and exciting outcomes!

Follow the link to discover the set we have prepared for you!

The Src homology 2 domain-containing protein tyrosine phosphatase (SHP2) is involved in various cellular signaling pathways, including those related to cell growth and differentiation. Recently, SHP2 has emerged as a target of interest in oncology for the treatment of certain cancers and other diseases characterized by dysregulated SHP2 activity with a single drug or in combination with inhibitors of other targets.

The drug candidate GDC-1971 was discovered from a previously known starting point using virtual screening and MD simulation. By targeting the allosteric site of SHP2, GDC-1971 demonstrates the potential to modulate SHP2 activity with high selectivity and improved safety profiles compared to traditional ATP-competitive inhibitors. This mode of action provides a basis for further exploration in the development of novel targeted therapies for various cancers.

Use chem-space.com/search to find off-the-shelf and Make-on-Demand molecules of your interest!